The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 12, 2017

Filed:

Apr. 04, 2014
Applicants:

Universite DE Montreal, Montreal, CA;

Rsem Limited Partnership, Montreal, CA;

Inventors:

Guy Sauvageau, Montreal, CA;

Josee Hebert, Ville Mont-Royal, CA;

Caroline Pabst, Montreal, CA;

Assignees:

UNIVERSITE DE MONTREAL, Montréal, CA;

RSEM, LIMITED PARTNERSHIP, Montréal, CA;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61K 31/5377 (2006.01); G01N 33/50 (2006.01); A61K 31/522 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 31/522 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); G01N 33/5073 (2013.01);
Abstract

Novel methods for modulating acute myeloid leukemia stem/progenitor cell expansion and/or differentiation are disclosed. These methods are based on the use of aryl hydrocarbon receptor (AhR) modulators and/or compounds of formula I or II Screening assays to identify compounds that may be useful for inhibiting and/or eliminating AML initiating cells using AhR modulators and/or the compounds of formula I or II are also disclosed. The use of pharmaceutically acceptable agonists of the AhR for preventing or inhibiting minimal residual disease (MRD) in an AML patient is also disclosed.


Find Patent Forward Citations

Loading…